不同剂量沙美特罗替卡松对哮喘稳定期的疗效观察

目的：研究不同剂量的沙美特罗替卡松对哮喘稳定期的疗效。方法将2009年1月～2013年12月收治的486例哮喘稳定器患者随机分为A组（沙美特罗替卡松50μg/250μg）及B组（沙美特罗替卡松50μg/100μg），并联合给予茶碱缓释片。比较2组在治疗前和治疗10 d后日间哮喘症状评分及夜间哮喘症状评分以及治疗前，治疗后10 d、30 d 2组患者肺功能情况。结果治疗前，2组患者在一般情况及其他治疗方面无统计学差异，经过10 d的相关治疗后A组患者日间哮喘症状评分（1.351±0.568）分及夜间哮喘症状评分（0.982±0.213）分，对照组分别是（1.826±0.645）分和（1.465±0.253）分，A组均优于B组（P〈0.05），治疗后10 d及30 d时，A组在肺功能的改善程度也要优于B组（P〈0.05）。A组不良反应发生率13.11%，B组为11.98%，组间比较差异无统计学意义。结论沙美特罗替卡松（50μg/250μg）对治疗支气管哮喘稳定期有较好的效果，而沙美特罗替卡松对于相关症状及肺功能的改善更有意义。

Objective To explore the efficacy of different doses of Salmeterol and fluticasone propionate on the patients of stable asthma. Methods From January 2009 to December 2013, 486 cases of patients of stable asthma were divided into group A （salmeterol and fluticasone propionate 50μg/250μg） 244 cases and group B （salmeterol and fluticasone propionate 50μg/100μg） 242 cases. The two groups were also accepted the Theophylline sustained release tablet. Results Before treatment, there was no significantly different in the general case and other therapeutic areas between the two groups. After 10 days of treatment-related, the daytime asthma symptom scores and nighttime asthma symptom scores of group A were（1.351±0.568）points and（0.982±0.213）points, they were all better than that in the group B which were（1.826±0.645）points and（1.465±0.253） points （P〈0.05）. After 10 days and 30 days of treatment-related, the degree of improvement in lung function of group A were better than group B （P〈0.05）. The incidence of adverse reactions of group A was 13.11%, it was 11.98%in group B, the difference was not statistically significant between the two groups. Conclusion Salmeterol and fluticasone propionate has better effect on the stable asthma patients, the dose of 50μg/250μg has a better meaningful for improving symptoms and lung function.